Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (BEIGF) Invested Capital (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Invested Capital for 11 consecutive years, with $5.2 billion as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 54.68% to $5.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.2 billion through Dec 2025, up 54.68% year-over-year, with the annual reading at $5.2 billion for FY2025, 54.68% up from the prior year.
  • Invested Capital for Q4 2025 was $5.2 billion at BeOne Medicines, up from $4.2 billion in the prior quarter.
  • The five-year high for Invested Capital was $6.6 billion in Q4 2021, with the low at $3.4 billion in Q4 2024.
  • Average Invested Capital over 5 years is $4.6 billion, with a median of $4.3 billion recorded in 2024.
  • The sharpest move saw Invested Capital skyrocketed 57.1% in 2021, then plummeted 33.18% in 2022.
  • Over 5 years, Invested Capital stood at $6.6 billion in 2021, then tumbled by 33.18% to $4.4 billion in 2022, then decreased by 3.6% to $4.2 billion in 2023, then decreased by 20.48% to $3.4 billion in 2024, then surged by 54.68% to $5.2 billion in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $5.2 billion, $4.2 billion, and $4.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.